Hospital Clínic de Barcelona

Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. (2024) Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, et al. Journal article, Review article UNSTAINED WHITE BLOOD CELL CLASSIFICATION USING DEEP LEARNING (2023) Yu H, Forster F, Bhandary Panambur A, Merino A, Maier A, Marquardt G Conference contribution Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis (2023) Hench J, Mihic-Probst D, Agaimy A, Frank S, Meyer P, Hultschig C, Simi S, et al. Journal article IL-12 and IL-23 pathway inhibition in inflammatory bowel disease (2023) Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath M, Vande Casteele N Journal article, Review article Clinical implementation of RNA sequencing for Mendelian disease diagnostics (2022) Yépez VA, Gusic M, Kopajtich R, Mertes C, Smith NH, Alston CL, Ban R, et al. Journal article Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Saha S, Lilleker JB, Agarwal V, et al. Journal article, Letter Diagnostic Odyssey in an Adult Patient with Ophthalmologic Abnormalities and Hearing Loss: Contribution of RNA-Seq to the Diagnosis of a PEX1 Deficiency (2022) Munoz-Pujol G, Alforja-Castiella S, Casaroli-Marano R, Morales-Romero B, Garcia-Villoria J, Yepez VA, Gagneur J, et al. Journal article Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution